CONCLUSION
The SAVI-registries have shown that transapical implantation using the ACURATE TATM device is safe and effective in an all-comers setting with low mortality, pacemaker and PVL rates, and stable haemodynamics throughout follow-up. There was no relevant difference in outcomes between SAVI-1 and -2.